Drug intelligence / Profile preview

daratumumab + dexamethasone + ixazomib + pomalidomide

Development stage: Unknown
Lead developer: Janssen Biotech
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous, Oral

Overview

The combination of daratumumab, dexamethasone, ixazomib, and pomalidomide is an investigational quadruplet regimen studied primarily for the treatment of relapsed or refractory multiple myeloma. Daratumumab is a monoclonal antibody targeting CD38 on plasma cells; it induces cell death through immune-mediated mechanisms. Ixazomib is an oral proteasome inhibitor that disrupts protein degradation in cancer cells, leading to apoptosis. Pomalidomide is an immunomodulatory agent that enhances immune response against myeloma cells and inhibits angiogenesis. Dexamethasone is a synthetic glucocorticoid with anti-inflammatory and cytotoxic effects on lymphoid malignancies. This combination aims to leverage complementary mechanisms to improve response rates in patients who have received prior therapies[1][2][4].

Brand names: Darzalex (daratumumab)Ninlaro (ixazomib)Pomalyst (pomalidomide)Decadron (dexamethasone)
Other names: DIPd

Targets

GR (Glucocorticoid receptor)CD38 (Cluster of Differentiation 38)CRBN (Cereblon)PSMB5 (Proteasome subunit beta Type-5)

Beyond the preview

Go deeper on daratumumab + dexamethasone + ixazomib + pomalidomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on daratumumab + dexamethasone + ixazomib + pomalidomide.

Explore the full profile